These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

329 related items for PubMed ID: 17660216

  • 1. Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis.
    Tsujimura S, Saito K, Nawata M, Nakayamada S, Tanaka Y.
    Ann Rheum Dis; 2008 Mar; 67(3):380-8. PubMed ID: 17660216
    [Abstract] [Full Text] [Related]

  • 2. Clinical relevance of the expression of P-glycoprotein on peripheral blood lymphocytes to steroid resistance in patients with systemic lupus erythematosus.
    Tsujimura S, Saito K, Nakayamada S, Nakano K, Tanaka Y.
    Arthritis Rheum; 2005 Jun; 52(6):1676-83. PubMed ID: 15934077
    [Abstract] [Full Text] [Related]

  • 3. Tacrolimus, a calcineurin inhibitor, overcomes treatment unresponsiveness mediated by P-glycoprotein on lymphocytes in refractory rheumatoid arthritis.
    Suzuki K, Saito K, Tsujimura S, Nakayamada S, Yamaoka K, Sawamukai N, Iwata S, Nawata M, Nakano K, Tanaka Y.
    J Rheumatol; 2010 Mar; 37(3):512-20. PubMed ID: 20080907
    [Abstract] [Full Text] [Related]

  • 4. The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study.
    Klaasen R, Thurlings RM, Wijbrandts CA, van Kuijk AW, Baeten D, Gerlag DM, Tak PP.
    Arthritis Rheum; 2009 Nov; 60(11):3217-24. PubMed ID: 19877042
    [Abstract] [Full Text] [Related]

  • 5. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
    Sekiguchi N, Kawauchi S, Furuya T, Inaba N, Matsuda K, Ando S, Ogasawara M, Aburatani H, Kameda H, Amano K, Abe T, Ito S, Takeuchi T.
    Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148
    [Abstract] [Full Text] [Related]

  • 6. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab.
    Lequerré T, Jouen F, Brazier M, Clayssens S, Klemmer N, Ménard JF, Mejjad O, Daragon A, Tron F, Le Loët X, Vittecoq O.
    Rheumatology (Oxford); 2007 Mar; 46(3):446-53. PubMed ID: 16899502
    [Abstract] [Full Text] [Related]

  • 7. Early and late effect of infliximab on circulating dendritic cells phenotype in rheumatoid arthritis patients.
    Balanescu A, Radu E, Nat R, Regalia T, Bojinca V, Ionescu R, Balanescu S, Savu C, Predeteanu D.
    Int J Clin Pharmacol Res; 2005 Mar; 25(1):9-18. PubMed ID: 15864873
    [Abstract] [Full Text] [Related]

  • 8. Etanercept overcomes P-glycoprotein-induced drug resistance in lymphocytes of patients with intractable rheumatoid arthritis.
    Tsujimura S, Saito K, Nakayamada S, Tanaka Y.
    Mod Rheumatol; 2010 Apr; 20(2):139-46. PubMed ID: 19915943
    [Abstract] [Full Text] [Related]

  • 9. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor.
    Rioja I, Hughes FJ, Sharp CH, Warnock LC, Montgomery DS, Akil M, Wilson AG, Binks MH, Dickson MC.
    Arthritis Rheum; 2008 Aug; 58(8):2257-67. PubMed ID: 18668547
    [Abstract] [Full Text] [Related]

  • 10. Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients.
    van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Rustenburg F, Baggen JM, Verweij CL, Tak PP.
    Ann Rheum Dis; 2008 Apr; 67(4):563-6. PubMed ID: 18042642
    [Abstract] [Full Text] [Related]

  • 11. Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12.
    van Oosterhout M, Levarht EW, Sont JK, Huizinga TW, Toes RE, van Laar JM.
    Ann Rheum Dis; 2005 Apr; 64(4):537-43. PubMed ID: 15769913
    [Abstract] [Full Text] [Related]

  • 12. A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment.
    Durez P, Nzeusseu Toukap A, Lauwerys BR, Manicourt DH, Verschueren P, Westhovens R, Devogelaer JP, Houssiau FA.
    Ann Rheum Dis; 2004 Sep; 63(9):1069-74. PubMed ID: 15308515
    [Abstract] [Full Text] [Related]

  • 13. Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate.
    Parker A, Izmailova ES, Narang J, Badola S, Le T, Roubenoff R, Ginsburg GS, Maier A, Coblyn JS, Shadick NA, Weinblatt ME.
    J Rheumatol; 2007 Sep; 34(9):1817-22. PubMed ID: 17696278
    [Abstract] [Full Text] [Related]

  • 14. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis.
    Chopin F, Garnero P, le Henanff A, Debiais F, Daragon A, Roux C, Sany J, Wendling D, Zarnitsky C, Ravaud P, Thomas T.
    Ann Rheum Dis; 2008 Mar; 67(3):353-7. PubMed ID: 17644538
    [Abstract] [Full Text] [Related]

  • 15. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis.
    Vis M, Nurmohamed MT, Wolbink G, Voskuyl AE, de Koning M, van de Stadt R, Twisk JW, Dijkmans BA, Lems WF.
    J Rheumatol; 2005 Feb; 32(2):252-5. PubMed ID: 15693084
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of anti-CD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy.
    Bokarewa M, Lindholm C, Zendjanchi K, Nadali M, Tarkowski A.
    Scand J Immunol; 2007 Oct; 66(4):476-83. PubMed ID: 17850593
    [Abstract] [Full Text] [Related]

  • 17. Plasma adiponectin in patients with active, early, and chronic rheumatoid arthritis who are steroid- and disease-modifying antirheumatic drug-naive compared with patients with osteoarthritis and controls.
    Laurberg TB, Frystyk J, Ellingsen T, Hansen IT, Jørgensen A, Tarp U, Hetland ML, Hørslev-Petersen K, Hornung N, Poulsen JH, Flyvbjerg A, Stengaard-Pedersen K.
    J Rheumatol; 2009 Sep; 36(9):1885-91. PubMed ID: 19684150
    [Abstract] [Full Text] [Related]

  • 18. Rituximab therapy in patients with resistant rheumatoid arthritis: real-life experience.
    Jois RN, Masding A, Somerville M, Gaffney K, Scott DG.
    Rheumatology (Oxford); 2007 Jun; 46(6):980-2. PubMed ID: 17384180
    [Abstract] [Full Text] [Related]

  • 19. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis.
    Wolbink GJ, Voskuyl AE, Lems WF, de Groot E, Nurmohamed MT, Tak PP, Dijkmans BA, Aarden L.
    Ann Rheum Dis; 2005 May; 64(5):704-7. PubMed ID: 15485995
    [Abstract] [Full Text] [Related]

  • 20. Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drug.
    Hider SL, Owen A, Hartkoorn R, Khoo S, Back D, Silman AJ, Bruce IN.
    Ann Rheum Dis; 2006 Oct; 65(10):1390-3. PubMed ID: 16504991
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.